THE PREVALENCE OF ANTIPHOSPHOLIPID ANTIBODIES AND THEIR CORRELATION WITH CLINICAL, LABORATORY FINDINGS IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS

Abstract

Objective. To evaluate the prevalence of antiphospholipid antibodies (aPL Abs) in systemic lupus erythematosus (SLE) patients and the relationship between these Abs with clinical and laboratory findings.Methods. Cross-sectional descriptive study on 60 patients newly diagnosed with SLE according to SLICC 2012 criteria, at the Center for Allergy - Clinical Immunology, Bach Mai Hospital from October 2022 to August 2023. The aPL group were defined as positive for at least one aPL. The clinical manifestation and laboratory findings of the positive and negative aPL groups were compared. Results. 37/60 patients (61.67 %) had positive for at least one aPL Abs. The percentage of groups positive for single antibody aCL, LAC, β2GPI, aPL, double and triple antibodies are 46.67%, 30%, 20%, 11.67%, 35%, 18.33%, respectively. We found that positive aPL and LA Abs significantly correlated with chronic kidney disease as compare with negative group. Unfortunately, no significance was found in hematology, neurology, thromboembolism, obstetric pathology, or livedo manifestations between the two groups. Conclusion. 61.7% newly SLE diagnosis was positive for at least one aPL Abs and the presence of these Abs was independently associated with the risk chronic kidney disease in SLE patients.